Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

This study has been completed.
Information provided by:
GlaxoSmithKline Identifier:
First received: April 11, 2007
Last updated: December 15, 2011
Last verified: December 2011
A study to investigate the safety and tolerability of both single and multiple intravenous administration of GSK933776 in patients with Alzheimer's Disease.

Condition Intervention Phase
Alzheimer's Disease
Drug: GSK933776
Drug: Placebo to match GSK933776
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: A Randomised, Single-Blind, Placebo-Controlled Study to Investigate the Safety, Tolerability, Immunogenicity, Pharmacokinetics and Pharmacodynamics of Intravenous Infusion of GSK933776 in Patients With Alzheimer's Disease.

Resource links provided by NLM:

Further study details as provided by GlaxoSmithKline:

Primary Outcome Measures:
  • Adverse events. Changes suggesting potential adverse events detected in the physical & neurological examination, brain MRI, cognitive status, laboratory parameters, ECG & vital signs. [ Time Frame: 12 weeks for Part A; 34 weeks in Part B ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Plasma pharmacokinetic parameters of GSK933776. Pharmacodynamic effects of GSK 933776. CSF detectable levels of GSK933776. Effects of GSK933776 on plasma and CSF biomarkers. Titre & neutralising activity of anti-GSK933776 antibodies. Exploratory PET scan [ Time Frame: 12 weeks for Part A; 34 weeks in Part B ] [ Designated as safety issue: No ]

Enrollment: 50
Study Start Date: March 2007
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Part A
Part A will be a single-blind, single dose, placebo controlled, dose escalation study in up to five consecutive cohorts of Alzheimers Disease subjects. Each subject will receive a single infusion of GSK933776 or placebo. The dose for the first cohort will be 0.001 mg/kg. The proposed nominal doses for subsequent cohorts are 0.01, 0.1, 0.5 and 3 mg/kg, but these may be altered based on the outcome of the safety, tolerability, pharmacodynamic and pharmacokinetic data of the preceding group(s). The maximum possible dose will be 20 mg/kg, although the planned top dose is 18 mg/kg
Drug: GSK933776

Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.

Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg

Other Name: GSK933776A
Drug: Placebo to match GSK933776
Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
Experimental: Part B

Part B will be a single-blind, repeat dose, placebo controlled dose escalation design. It is proposed that there will be initially 3 cohorts of AD subjects. However up to 5 cohorts may be recruited if required in order to characterise GSK933776 fully.Each cohort will consist of eight subjects (six active, two placebo) who will each receive a maximum of three infusions of GSK933776 or placebo. Dosing in Part B may proceed in parallel with Part A following satisfactory review of minimum data sets as below:

First cohort in Part B: at least 3 weeks' data from the Part A dose that is the same dose level as that planned for Part B Second cohort in Part B: at least 3 weeks PK data and 8 weeks safety data following the first dose from all the subjects on active treatment in the preceding Part B cohort plus a satisfactory outcome of the PIB Subsequent cohorts in Part B: at least 3 weeks PK data and 8 weeks safety data follow

Drug: GSK933776

Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.

Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg

Other Name: GSK933776A
Drug: Placebo to match GSK933776
Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.


Ages Eligible for Study:   55 Years to 80 Years   (Adult, Senior)
Genders Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • Male or female subject with a clinical diagnosis of probable Alzheimer's disease
  • Subject has mild AD with Mini Mental State Examination (MMSE) score 18-26 inclusive at the screening visit.
  • Age between 55 and 80 years.
  • Female subjects must be post-menopausal or surgically sterile.
  • Male subjects whose partner is of child-bearing potential or have been menopausal for <2 years must use an adequate form of contraception.
  • Subject has the ability to comply with procedures for cognitive and other testing & is fluent in the language used for the administration of the cognitive tests.
  • Subject lives with (or has substantial periods of contact with) a permanent caregiver who is willing to oversee the subject's compliance with protocol-specified procedures and study medication, and report on subject's status.
  • Subject has provided full written informed consent prior to the performance of any protocol-specified procedure.
  • Caregiver has provided a full written informed consent on his/her own behalf prior to the performance of any protocol-specified procedure.

Exclusion criteria:

  • History and/or evidence of any other central nervous system (CNS) disorder that could be interpreted as a cause of dementia.
  • Subjects currently living in a nursing home.
  • Subjects who are unable to provide informed consent due to cognitive status
  • Screening brain MRI with 1 or more of the following conditions: not consistent with AD, evidence of other CNS conditions, shows more than minimal vascular changes, more than 3 microhaemorrhage lesions.
  • Focal findings on the neurological exam.
  • Any contraindication to lumbar puncture.
  • History or evidence of significant psychiatric illness such as schizophrenia or bipolar affective disorder or significant neurological disease other than AD.
  • TIA/stroke in the last 3 years, type 1 or type 2 diabetes mellitus, active cardiovascular disease, or other uncontrolled risk factors for stroke.
  • Current or recent drug or alcohol abuse or dependence or recent or remote history of the same if that could be a contributing factor to the dementia.
  • History or evidence of any significant autoimmune disease or disorder.
  • History of seizures (excluding febrile seizures in childhood), current blood clotting or bleeding disorder or conditions that predispose to these (e.g. cancer), current clinically significant systemic illness or significant infection within 30 days that is likely to result in deterioration of the subject's condition or affect the subject's safety during the study.
  • History of cerebral amyloid antiopathy and/or hypertensive cerebral haemorrhage or with a known risk of intercerebral haemorrhage/microhaemorrhage.
  • Treatment which cholinesterase inhibitors, memantine or selegiline unless the therapy was instituted at least 3 months prior to the administration of GSK933776, at a stable dosage in the 2 months prior and the same regimen will be continued for the duration of the trial and the subject is free from any clinically significant side effects attributable to the drug.
  • Subjects who have discontinued cholinesterase inhibitors, memantine, cognitive enhancing agents, or drugs that potentially affect cognition in the 60 days prior to screening.
  • Unless maintained on a stable dose regimen for at least 30 days prior to screening, any other medications with the potential to affect cognition.
  • Use of drugs with platelet anti-aggregant or anti-coagulant properties (excluding the use of aspirin 325 mg/day or less), anticonvulsants for seizures or narcotic medication.
  • History of or current chronic use of systemic steroids or other immunosuppressants.
  • Prior participation in clinical investigations involving therapeutic monoclonal antibodies or proteins derived from monoclonal antibodies or any investigations of treatments or use of experimental medications for AD or any other investigational medication or device within 60 days prior to screening or within 5 half-lives of use of such a medication prior to screening, whichever is longer.
  • Contraindications for MRI: pacemaker, aneurysm clips, artificial heart valves, other metal foreign body, claustrophobia, etc.
  • Smoking more than 20 cigarettes or equivalent per day.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00459550

Australia, Victoria
GSK Investigational Site
Heidelberg Heights, Victoria, Australia, 3084
Australia, Western Australia
GSK Investigational Site
Fremantle, Western Australia, Australia, 6160
GSK Investigational Site
Lørenskog, Norway, 1478
GSK Investigational Site
Malmö, Sweden, SE-205 02
GSK Investigational Site
Mölndal, Sweden, SE-431 41
GSK Investigational Site
Stockholm, Sweden, se-141 86
Sponsors and Collaborators
Study Director: GSK Clinical Trials GlaxoSmithKline
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure Identifier: NCT00459550     History of Changes
Other Study ID Numbers: 106006 
Study First Received: April 11, 2007
Last Updated: December 15, 2011
Health Authority: Australia: Human Research Ethics Committee
Sweden: Medical Products Agency

Keywords provided by GlaxoSmithKline:
Alzheimer's Disease
First Time in Human (FTIH) Study

Additional relevant MeSH terms:
Alzheimer Disease
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Neurodegenerative Diseases
Neurocognitive Disorders
Mental Disorders processed this record on January 14, 2017